ArticleJournal of cellular and molecular medicine2019
Evodiamine inhibits RANKL-induced osteoclastogenesis and prevents ovariectomy-induced bone loss in mice.
Article in Journal of cellular and molecular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- The role of active constituents of in traditional Chinese medicine for primary osteoporosis: a mechanistic review.Frontiers in endocrinology · 2025Pooled it
- Tirzepatide, a dual GLP-1 and GIP receptor agonist, promotes bone loss in obese mice via gut microbial-related metabolites.Journal of orthopaedic translation · 2025Article
- Euodiae Fructus: a review of botany, application, processing, phytochemistry, quality control, pharmacology, and toxicology.Frontiers in pharmacology · 2025Review
- Anti‑osteoclastogenic effect of fermented mealworm extract by inhibiting RANKL‑induced NFATc1 action.Experimental and therapeutic medicine · 2024Article
- Evodiamine ameliorates intervertebral disc degeneration through the Nrf2 and MAPK pathways.Cytotechnology · 2024Article
- Small-molecule amines: a big role in the regulation of bone homeostasis.Bone research · 2023Review
- Traditional Chinese medicine Euodiae Fructus: botany, traditional use, phytochemistry, pharmacology, toxicity and quality control.Natural products and bioprospecting · 2023Review
- Bioinformatics analysis identification ofExperimental and therapeutic medicine · 2022Article
- P2X7 receptor knockdown suppresses osteoclast differentiation by inhibiting autophagy and CaMolecular medicine reports · 2022Article
- Anti-Osteoclast Effect of Exportin-1 Inhibitor Eltanexor on Osteoporosis Depends on Nuclear Accumulation of IκBα-NF-κB p65 Complex.Frontiers in pharmacology · 2022Article
- A CREB1-miR-181a-5p loop regulates the pathophysiologic features of bone marrow stromal cells in fibrous dysplasia of bone.Molecular medicine (Cambridge, Mass.) · 2021Article
- Peiminine Suppresses RANKL-Induced Osteoclastogenesis by Inhibiting the NFATc1, ERK, and NF-κB Signaling Pathways.Frontiers in endocrinology · 2021Article
- Inhibitory Effects of Rhaponticin on Osteoclast Formation and Resorption by Targeting RANKL-Induced NFATc1 and ROS Activity.Frontiers in pharmacology · 2021Article
- Cytisine attenuates bone loss of ovariectomy mouse by preventing RANKL-induced osteoclastogenesis.Journal of cellular and molecular medicine · 2020Article
- Guaiacol suppresses osteoclastogenesis by blocking interactions of RANK with TRAF6 and C-Src and inhibiting NF-κB, MAPK and AKT pathways.Journal of cellular and molecular medicine · 2020Article
- Osthole-loaded N-octyl-O-sulfonyl chitosan micelles (NSC-OST) inhibits RANKL-induced osteoclastogenesis and prevents ovariectomy-induced bone loss in rats.Journal of cellular and molecular medicine · 2020Article
- Modulation of bone turnover aberration: A target for management of primary osteoporosis in experimental rat model.Heliyon · 2020Article
- Imperatorin promotes osteogenesis and suppresses osteoclast by activating AKT/GSK3 β/β-catenin pathways.Journal of cellular and molecular medicine · 2020Article
- Communications Between Bone Marrow Macrophages and Bone Cells in Bone Remodeling.Frontiers in cell and developmental biology · 2020Review
- Corrigendum.Journal of cellular and molecular medicine · 2019Article
Corrections and comments
- Erratum issuedCorrigendum.2019
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postmenopausal osteoporosis (PMO) is a progressive bone disease characterized by the over-production and activation of osteoclasts in elderly women. In our study, we investigated the anti-osteoclastogenic effect of evodiamine (EVO) in vivo and in vitro, as well as the underlying mechanism. By using an in vitro bone marrow macrophage (BMM)-derived osteoclast culture system, we found that EVO inhibited osteoclast formation, hydroxyapatite resorption and receptor activator of NF-κB ligand (RANKL)-induced osteoclast marker gene and protein expression. Mechanistically, we found that EVO inhibited the degradation and RANKL-induced transcriptional activity of IκBα. RANKL-induced Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.